Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06422689 · ClinicalTrials.gov registry record · Phase 4

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

A Phase 4 study of Asthma, sponsored by AstraZeneca.

Active
Registry status
Phase 4
Development phase
1,507
Enrollment target
11
Study locations

NCT06422689 is a Phase 4 study of Asthma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,507 participants, roughly in line with the 1,559-participant average among 374 other Asthma trials with a reported enrollment target. The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06422689, a Phase 4 study of Asthma, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
1,507 participants
Enrollment target
11
Study locations

Study Summary

ANCHOR is a prospective, phase IV, interventional, single-arm, open-label study of 1,500 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonide inhalation aerosol as rescue therapy.

Conditions Studied

Asthma

Interventions

  • DRUG Albuterol and budesonide inhalation aerosol

Study Locations (11)

California

  • Research Site - North Hollywood
  • Research Site - Walnut Creek

Michigan

  • Research Site - Ann Arbor
  • Research Site - Flint

North Carolina

  • Research Site - Asheville
  • Research Site - Greenville

Kentucky

  • Research Site - Louisville

Massachusetts

  • Research Site - Boston

Minnesota

  • Research Site - Minneapolis

Pennsylvania

  • Research Site - DuBois

Texas

  • Research Site - Austin

Trial Details

FieldValue
Enrollment Target 1,507 participants
Start Date 2024-05-10
Est. Completion 2026-04-29
Phase Phase 4

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06422689

The ClinicalTrials.gov registry entry for NCT06422689 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 1,507 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,559-participant average among 374 other Asthma trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Albuterol and budesonide inhalation aerosol is the first listed.

NCT06422689 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Michigan, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06422689 about?

NCT06422689 is a clinical study titled "Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care". ANCHOR is a prospective, phase IV, interventional, single-arm, open-label study of 1,500 adult participants with symptomatic asthma requiring the use of rescue therapy aimed to compare the asthma exacerbation rates before and after switching from albuterol or levalbuterol to albuterol plus budesonid...

What is the current status of trial NCT06422689?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 1,507 participants. The study started on 2024-05-10. Estimated completion is 2026-04-29.

What conditions does trial NCT06422689 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06422689?

The interventions under investigation include: Albuterol and budesonide inhalation aerosol (DRUG).

Who is sponsoring clinical trial NCT06422689?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06422689 being conducted?

This trial has 11 study locations across California, Kentucky, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.